Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Dariush Daneshvar, MD, FRCPA"'
Autor:
Tamkin Ahmadzada, BE, Wendy A. Cooper, BScMed, M.B.B.S., PhD, FRCPA, Mikaela Holmes, BBiomedSc, Annabelle Mahar, M.B.B.S., FRCPA, Helen Westman, MPH, Anthony J. Gill, MD, FRCPA, Ina Nordman, M.B.B.S., FRACP, M(Med)Sc, Po Yee Yip, MbChB., FRACP, PhD, Abhijit Pal, BSc (Hons), M.B.B.S., FRACP, Rob Zielinski, FRACP, M.B.B.S., Hons, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin Epi), PhD, FRACP, Adnan Nagrial, M.B.B.S., PhD, Dariush Daneshvar, MD, FRCPA, Daniel Brungs, M.B.B.S., MMed (Clin Epi), FRCPA, Deme Karikios, BSc, M.B.B.S., FRACP, PhD, Vesna Aleksova, BMedSc, Juliet Burn, M.B.B.S., FRCPA, MIAC, Rebecca Asher, MSc, Georges E. Grau, MD, PhD, Elham Hosseini-Beheshti, MSc, PhD, Glen Reid, PhD, Stephen Clarke, MD, PhD, FRACP, Steven Kao, BHB, MbChB., PhD, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 4, Pp 100075- (2020)
Introduction: We investigated the efficacy and toxicity of pembrolizumab in patients with mesothelioma from a real-world Australian population. We aimed to determine clinical factors and predictive biomarkers that could help select patients who are l
Externí odkaz:
https://doaj.org/article/8decaaa69f954183bf0aaa4a972c4d8b